Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies

Immune checkpoint inhibitors (ICIs), especially those targeting the programmed-death 1 (PD-1) receptor and its ligands, have become indispensable agents in solid tumor anti-cancer therapy. Concerning hematological malignancies, only nivolumab and pembrolizumab have been approved for the treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hradska, Katarina, Hajek, Roman, Jelinek, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414817/
https://www.ncbi.nlm.nih.gov/pubmed/34483944
http://dx.doi.org/10.3389/fphar.2021.733890

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8414817/
https://www.ncbi.nlm.nih.gov/pubmed/34483944
http://dx.doi.org/10.3389/fphar.2021.733890

Ejemplares similares